• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在两阶段成组序贯设计中,当试验提前终止时,在假设渐近正态性的情况下使用先验信息进行条件估计。

Conditional estimation using prior information in 2-stage group sequential designs assuming asymptotic normality when the trial terminated early.

作者信息

Shimura Masashi, Maruo Kazushi, Gosho Masahiko

机构信息

Data Science Department, Taiho Pharmaceutical Co, Ltd, Chiyoda-ku, Tokyo, Japan.

Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan.

出版信息

Pharm Stat. 2018 Sep;17(5):400-413. doi: 10.1002/pst.1859. Epub 2018 Apr 23.

DOI:10.1002/pst.1859
PMID:29687592
Abstract

Two-stage designs are widely used to determine whether a clinical trial should be terminated early. In such trials, a maximum likelihood estimate is often adopted to describe the difference in efficacy between the experimental and reference treatments; however, this method is known to display conditional bias. To reduce such bias, a conditional mean-adjusted estimator (CMAE) has been proposed, although the remaining bias may be nonnegligible when a trial is stopped for efficacy at the interim analysis. We propose a new estimator for adjusting the conditional bias of the treatment effect by extending the idea of the CMAE. This estimator is calculated by weighting the maximum likelihood estimate obtained at the interim analysis and the effect size prespecified when calculating the sample size. We evaluate the performance of the proposed estimator through analytical and simulation studies in various settings in which a trial is stopped for efficacy or futility at the interim analysis. We find that the conditional bias of the proposed estimator is smaller than that of the CMAE when the information time at the interim analysis is small. In addition, the mean-squared error of the proposed estimator is also smaller than that of the CMAE. In conclusion, we recommend the use of the proposed estimator for trials that are terminated early for efficacy or futility.

摘要

两阶段设计被广泛用于确定一项临床试验是否应提前终止。在这类试验中,常采用最大似然估计来描述试验治疗与对照治疗之间的疗效差异;然而,已知这种方法存在条件偏差。为减少此类偏差,已提出一种条件均值调整估计量(CMAE),不过,当中期分析因疗效而提前终止试验时,剩余偏差可能仍不可忽略。我们通过扩展CMAE的理念,提出一种用于调整治疗效果条件偏差的新估计量。该估计量通过对中期分析时获得的最大似然估计值与计算样本量时预先设定的效应量进行加权来计算。我们在各种中期分析因疗效或无效性而提前终止试验的情况下,通过分析研究和模拟研究来评估所提出估计量的性能。我们发现,当中期分析时的信息时间较短时,所提出估计量的条件偏差小于CMAE的条件偏差。此外,所提出估计量的均方误差也小于CMAE的均方误差。总之,对于因疗效或无效性而提前终止的试验,我们建议使用所提出的估计量。

相似文献

1
Conditional estimation using prior information in 2-stage group sequential designs assuming asymptotic normality when the trial terminated early.在两阶段成组序贯设计中,当试验提前终止时,在假设渐近正态性的情况下使用先验信息进行条件估计。
Pharm Stat. 2018 Sep;17(5):400-413. doi: 10.1002/pst.1859. Epub 2018 Apr 23.
2
Comparison of conditional bias-adjusted estimators for interim analysis in clinical trials with survival data.具有生存数据的临床试验中期分析中条件偏差调整估计量的比较。
Stat Med. 2017 Jun 15;36(13):2067-2080. doi: 10.1002/sim.7258. Epub 2017 Feb 17.
3
Assessment of Hazard Ratios in Oncology Clinical Trials Terminated Early for Superiority: A Systematic Review.评估因优越性而提前终止的肿瘤学临床试验中的危害比:系统评价。
JAMA Netw Open. 2020 Jun 1;3(6):e208633. doi: 10.1001/jamanetworkopen.2020.8633.
4
Estimation of the odds ratio from multi-stage randomized trials.多阶段随机临床试验中优势比的估计。
Pharm Stat. 2024 Sep-Oct;23(5):662-677. doi: 10.1002/pst.2378. Epub 2024 Mar 10.
5
Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection.两阶段自适应设计中基于中期治疗选择的收缩估计。
Stat Med. 2013 May 10;32(10):1677-90. doi: 10.1002/sim.5463. Epub 2012 Jun 29.
6
Point estimation following a two-stage group sequential trial.两阶段分组序贯试验后的点估计。
Stat Methods Med Res. 2023 Feb;32(2):287-304. doi: 10.1177/09622802221137745. Epub 2022 Nov 16.
7
Point estimation in adaptive enrichment designs.适应性富集设计中的点估计
Stat Med. 2017 Nov 10;36(25):3935-3947. doi: 10.1002/sim.7412. Epub 2017 Aug 7.
8
Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome.缺乏获益停止规则对以时间为结局的两臂多阶段(TAMS)试验治疗效果估计的影响。
Trials. 2013 Jan 23;14:23. doi: 10.1186/1745-6215-14-23.
9
Statistical Inference for a Two-Stage Adaptive Seamless Design Using Different Binary Endpoints.使用不同二元终点的两阶段自适应无缝设计的统计推断
Stat Med. 2025 Mar 15;44(6):e70003. doi: 10.1002/sim.70003.
10
An MSE-reduced estimator for the response proportion in a two-stage clinical trial.两阶段临床试验中响应比例的均方误差降低估计量。
Pharm Stat. 2011 May-Jun;10(3):277-9. doi: 10.1002/pst.414. Epub 2010 Feb 5.

引用本文的文献

1
Adjustment of Conditional Bias in Hazard Ratios for Group Sequential Testing of Progression-Free Survival and Overall Survival.无进展生存期和总生存期成组序贯检验风险比中条件偏倚的调整
Stat Med. 2025 May;44(10-12):e70112. doi: 10.1002/sim.70112.
2
Point estimation for adaptive trial designs I: A methodological review.自适应试验设计的点估计 I:方法学综述。
Stat Med. 2023 Jan 30;42(2):122-145. doi: 10.1002/sim.9605. Epub 2022 Nov 30.
3
Point estimation following a two-stage group sequential trial.两阶段分组序贯试验后的点估计。
Stat Methods Med Res. 2023 Feb;32(2):287-304. doi: 10.1177/09622802221137745. Epub 2022 Nov 16.
4
Assessment of Hazard Ratios in Oncology Clinical Trials Terminated Early for Superiority: A Systematic Review.评估因优越性而提前终止的肿瘤学临床试验中的危害比:系统评价。
JAMA Netw Open. 2020 Jun 1;3(6):e208633. doi: 10.1001/jamanetworkopen.2020.8633.